Bayer has announced an agreement to acquire the cell therapy company BlueRock Therapeutics, and plans to open a clinical trial of a potential Parkinson’s stem cell-based treatment this year.. BlueRock, which will remain an independent entity under the plan, has a portfolio that focuses on engineered stem cell therapies to treat illnesses in the fields of neurology, cardiology and immunology. Bayer AG has agreed to buy the shares in BlueRock Therapeutics it didn't already own, valuing the company at up to $1 billion, it said Thursday.. Bayer, which already held 40.8% in BlueRock, will buy the remaining shares in the biotechnology company for about $240 million in cash and an additional $360 million in milestone payments.
BlueRock Therapeutics was established in December 2016 with initial seed investments from Bayer AG and Versant Ventures. BlueRock Therapeutics was founded in 2016 by Versant Ventures and Bayer AG and capitalized with one of the largest-ever Series A financings in biotech history by Bayer AG (through its Leaps by Bayer unit) and Versant Ventures. BlueRock Therapeutics was founded in 2016 by Versant Ventures and Bayer AG and capitalized with one of the largest-ever Series A financings in biotech history by Bayer AG (through its Leaps by Bayer unit) and Versant Ventures. Bayer AG and BlueRock Therapeutics today announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell (iPSC) platform. Bayer Acquires BlueRock Therapeutics On Aug 9, 2019. BlueRock Therapeutics' culture is defined by scientific innovation, highest ethical standards and an urgency to bring transformative treatments to all who would benefit. By Cristina Roca . Bayer is set to pay $240 million (€214 million) upfront to buy the remaining stake in its cell therapy joint venture, BlueRock Therapeutics. Bayer AG and BlueRock Therapeutics announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell (iPSC) platform. Bayer currently has more than 2,000 employees in Whippany. Bayer AG acquired Cambridge, Massachusetts-based cell therapy company BlueRock Therapeutics.. Bayer Acquires BlueRock Therapeutics On Aug 9, 2019. Bayer has announced an agreement to acquire the cell therapy company BlueRock Therapeutics, and plans to open a clinical trial of a potential Parkinson’s stem cell-based treatment this year.. BlueRock, which will remain an independent entity under the plan, has a portfolio that focuses on engineered stem cell therapies to treat illnesses in the fields of neurology, cardiology and immunology. Bayer acquires BlueRock Therapeutics to build leading position in cell therapy - Implied total company value of up to USD 1 billion, inclusive of 40.8 percent stake currently held by Bayer Bayer AG will fully acquire BlueRock Therapeutics, a privately held biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell (iPSC) platform. BlueRock Therapeutics was founded in 2016 by Versant Ventures and Bayer AG and capitalized with one of the largest-ever Series A financings in biotech history by Bayer AG (through its Leaps by Bayer unit) and Versant Ventures. Bayer AG will fully acquire BlueRock Therapeutics, a privately held biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell (iPSC) platform. Details Bayer 08 August 2019 Bayer AG and BlueRock Therapeutics today announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell (iPSC) platform.
Copyright 2020 bluerock therapeutics%2C bayer